Clinical Data In 2014 Could Trigger Private Biotech Financings
This article was originally published in Start Up
Executive Summary
Despite difficulties financing late-stage trials, several private companies are expecting Phase II and III data that should help shape public investor sentiment this year. Familiar compounds in new guises lead the way.